Table 2.
Association of implicated genetic risk factors with PCSM (multivariable analysis).
| Genes | Subjects, N. (%) | PCSM, N. (per 100,000 person-year) | HR (95% CI)a | p-valuea |
|---|---|---|---|---|
| NCCN-DDR Tier-1 genes* | ||||
| Non-carriers | 14,475/14,644 (98.85) | 1531 (1448.55) | 1.00 (ref) | |
| Carriers | 169/14,644 (1.15) | 50 (4699.57) | 3.50 (2.60-4.71) | 2.20E-16 |
| NCCN-DDR Tier-2 genes** | ||||
| Non-carriers | 14,230/14,644 (97.17) | 1518 (1461.68) | 1.00 (ref) | |
| Carriers | 414/14,644 (2.83) | 63 (2170.58) | 1.51 (1.17-1.95) | 1.60E-03 |
| KLK3-I179T | ||||
| Non-carriers | 13,044/14,644 (89.07) | 1368 (1428.54) | 1.00 (ref) | |
| Carriers | 1600/14,644 (10.93) | 213 (1937.54) | 1.25 (1.08-1.44) | 2.70E-03 |
*Tier 1 genes: BRCA2, MSH6, PALB2.
**Tier 2 genes: ATM, BRCA1, CHEK2, MLH1, MSH2, PMS2, TP53.
a. Fine-Gray models accounting for competing risks (death) using age as the time scale, with left-truncation at age of diagnosis, and adjusted for top 10 PCs,
PCSM prostate cancer-specific mortality, IQR interquartile range.